Custom RNA vaccines take on aggressive breast cancer in first human test
NCT ID NCT02316457
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This first-in-human trial tested personalized RNA vaccines designed to target each patient's unique tumor mutations in triple negative breast cancer (TNBC). 42 participants received two custom-made vaccines to stimulate their immune system. The main goal was to check safety and tolerability, with secondary focus on immune response. The study is completed, but results are not yet widely available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized RNA vaccine (IVAC_W_bre1_uID and IVAC_M_uID)
What this could lead to
If successful, this approach could lead to a personalized immunotherapy that trains the immune system to fight triple negative breast cancer, potentially improving outcomes for patients with this aggressive cancer.
What could go wrong
This is an early Phase 1 trial focused on safety, not effectiveness. The vaccines are custom-made for each patient, which is complex and may not work for everyone. Side effects or limited immune response are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER (TRIPLE NEGATIVE BREAST CANCER (TNBC)) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dr. Horst Schmidt-Kliniken Wiesbaden
Wiesbaden, 65199, Germany
-
Johannes Gutenberg University
Mainz, RLP, 55131, Germany
-
National Center for Tumor Diseases (NCT)
Heidelberg, 69120, Germany
-
Uppsala University Hospital
Uppsala, 75185, Sweden